Researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, have shown how immune system cells, macrophages, have a key role in the regulation of obesity and the findings could be useful in the development of new treatments for people with obesity and overweight, and for some associated pathologies, including fatty liver disease and type 2 diabetes.
Metabolic surgery benefits people with morbid obesity and hypertension reducing their risk of major adverse cardiovascular event (MACE), according to a study, ‘Association between metabolic surgery and cardiovascular outcome in patients with hypertension: A nationwide matched cohort study’, published in PLoS Med.
Researchers at the Medical College of Georgia scientists are investigating an emerging obesity paradox that a new generation of HIV drugs appear to cause weight gain, which appears to limit, rather than increase patients' already significant risk of developing cardiovascular disease. Although these newer generation of HIV drugs have turned the once-lethal infection into a chronic condition, cardiovascular disease has emerged as the leading cause of death in these individuals.
The combined effects of the body's microbiota working together with COVID-19 in the lungs could explain the severity of the disease in people with obesity and diabetes, according to a paper, 'Obesity and diabetes as comorbidities for COVID-19: Underlying mechanisms and the role of viral–bacterial interactions', published in eLife,
ReShape Lifesciences has announced that the first 25 healthcare providers have partnered with ReShapeCare since the programme's launch in June of this year, allowing referrals of their patients to the reimbursable, virtual weight-management programme. Patients within the programme include individuals currently receiving treatment, those who may have lost continuity of care, patients pursuing bariatric surgery and those involved in a medically supervised weight-loss programme.
Ethicon has launched the of Echelon Endopath Staple Line Reinforcement (SLR), a novel buttressing device designed to further strengthen staple lines and reduce potential complications during bariatric, thoracic and general surgical procedures, in the US. This is the company’s first buttress solution designed for use with its own industry-leading Echelon Flex Powered Staplers with GST reloads, which have been associated with a lower rate of air leaks and bleeding complications1,2.
People who have been diagnosed with obstructive sleep apnoea could be at increased risk of adverse outcomes from COVID-19, according to a study from the University of Warwick. The conclusion is drawn from a systematic review of studies that reported outcomes for COVID-19 patients that were also diagnosed with obstructive sleep apnoea.
A study in mice has found that the estimated ten trillion bacteria living in your digestive system may shape your metabolism, as well as directly influencing biological processes from bowel movements to behaviour. Researchers in Daniel Mucida's Laboratory of Mucosal Immunology at Rockefeller University, have identified a particular type of gut neuron that controls blood sugar levels, influencing appetite.
A novel hydrogel platform technology to treat overweight, obesity and other chronic metabolic diseases, was the subject pf one oral presentation and two poster presentations showcasing notable efficacy data for Plenity (Gelesis 100) at the European and International Congress on Obesity (ECO-ICO 2020).
GI Windows Medical, a clinical-stage, privately-held medical device company, has raised US$16.4 million Series A-1 financing. The financing attracted Johnson & Johnson Innovation along with Sonder Capital, GT Healthcare, JC Investco and one additional strategic investor. In addition to the institutional financing, GI Windows also received investments from existing shareholders as well as new investors, the Kennedy Trust and Coleman Trust.
Young adults who have experienced weight stigma have more distress and maladaptive eating behaviours during the pandemic, regardless of their body size. Research from the UConn Rudd Center for Food Policy and Obesity and the University of Minnesota shows that young adults who experienced weight stigma before the pandemic have higher levels of depressive symptoms, stress, eating as a coping strategy, and are more likely to binge-eat during COVID-19, compared to those who have not experienced weight stigma.
ReShape Lifesciences has announced preclinical research demonstrating the its investigational Diabetes Bloc-Stim Neuromodulation (DBSN) proprietary device for the treatment of type 2 diabetes mellitus (T2DM) was well-tolerated and met the study endpoints. The study was conducted as a part of the National Institutes of Health (NIH) Small Business Innovation Research Phase I grant that was previously awarded in August 2019.
A pooled analysis of large-scale registry studies by UK researchers suggests that bariatric surgery is associated with reduced long-term all-cause mortality and incidence of obesity-related diseases (new-onset diabetes, high blood pressure, high cholesterol and heart disease etc) in patients with obesity for the whole operated population. The outcomes highlight that broader (increased) access to bariatric surgery for people with obesity may reduce the long-term sequelae of this disease and provide population-level benefits.
Young adults with underlying conditions such as morbid obesity, diabetes and hypertension are at the highest risk of being placed on a ventilator or dying from COVID-19, according to a study of 3,000 hospitalized patients aged 18 to 34. It confirmed first and foremost that black and Hispanic people have been the worst affected by the pandemic: they accounted for 57 percent of all young adults who were hospitalized and 49 percent of those who died or needed ventilation, representing about a third of all young people.
The number of people with pre-diabetes who go on to develop type 2 diabetes has been reducing over the past two decades, according to a study led by University of Manchester epidemiologists. However, the changes, according to lead author, Dr Rathi Ravindrarajah, are likely to be attributed to changes in the definition of pre-diabetes and recording practices, as well as preventative work by the NHS., such as the NHS Diabetes Prevention Programme.
Probiotics may help children and adolescents with obesity lose weight when taken alongside a calorie-controlled diet, according to a study presented at e-ECE (European Society of Endocrinology) 2020.
Researchers led by Imperial College Healthcare NHS Trust, London, UK, are looking to recruit participants to enrol in the Bariatric surgery vs. Medical care for obesity and polycystic ovarian syndrome related infertility (BAMBINI) randomised clinical trial. The study will examine the effects of bariatric surgery vs. lifestyle intervention in premenopausal women over the age of 18 with a diagnosis of polycystic ovarian syndrome (POCS) with a body mass index ≥35kg/m2 and less than eight menstrual periods a year.
People with obesity who intentionally (not because of illness) lost an average (median) 13% of their initial body weight reduced their relative risk of developing type 2 diabetes by 42%-44%, sleep apnoea by 22%-27%, high blood pressure by 18%-25%, and dyslipidaemia by 20-22%, according to a study of over 550,000 adults in primary care in the UK. The study authors believe it is the first of its kind to quantify the benefits of intentional weight loss on the risk of obesity-related conditions in real-world clinical practice.
People with obesity who gain weight have a tendency to perceive their own body size as smaller than it actually is compared to those who maintain a stable weight, according to research following more than 2,000 people with obesity from the Swedish Obese Subjects (SOS) study over ten years.
A detailed analysis of UK data from a global obesity study (the ACTION-IO study) has shown that, on average, people with obesity (PwO) in the UK were struggling with their weight for nine years before they sought help from a healthcare professional/HCP, much longer than the global average of six years. This delay puts PwO at additional risk of developing obesity-related conditions such as type 2 diabetes (T2D), obstructive sleep apnoea (OSA) and cancer. Additionally, more than half of the PwO had never discussed their weight with an HCP.